Work

Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.e21048

Authors: Elizabeth Ruth Plummer, Natalie Cook, Hendrik-Tobias Arkenau, Jason M. Melear, Charles H. Redfern, Alexander I. Spira, Ki Y. Chung, Geoffrey Shapiro, Tufia C. Haddad, Suresh S. Ramalingam, Robert Wesolowski, Thomas Goddemeier, Martin H. Falk, Emma Dean

Institutions: Freeman Hospital, The Christie Hospital, The Christie NHS Foundation Trust, Sarah Cannon Research Institute, Texas Oncology, Sharp Memorial Hospital, Virginia Cancer Specialists, Prisma Health, Dana-Farber Cancer Institute, Mayo Clinic, Emory University, Winship Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Merck KGaA, Darmstadt (Germany)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889859034

Cites:

Cited by: 4

Related to: 10